EW
EWTX.US Edgewise Therapeutics Inc
- Market cap
- USD 5.03B
- P/E
- 5.5x
- P/B
- 3.07x
- ROE
- 86.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is EWTX.US undervalued?
Graham numberEWTX.US trades 13.5% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Edgewise Therapeutics Inc fundamental analysis
No fundamental analysis for Edgewise Therapeutics Inc yet.
Edgewise Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Edgewise Therapeutics Inc
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyo…
Full company profileEdgewise Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Edgewise Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -123K | -185K | -272K | -538K | -1.73M | -2.29M | -2.27M | - |
| Operating Income | -9.92M | -17.2M | -43.2M | -22.1M | -114M | -159M | -191M | -216M |
| EBITDA | -9.80M | -17.0M | -42.9M | -21.5M | -98.4M | -132M | -166M | 1.62B |
| Net Income | -9.49M | -17.1M | -42.1M | -15.4M | -100M | -134M | -168M | 1.41B |
| EPS | -0.19 | -0.35 | -0.85 | -0.29 | -1.57 | -1.45 | -1.63 | 12 |
| Balance Sheet | ||||||||
| Total Assets | 24.5M | 131M | 285M | 367M | 340M | 487M | 553M | 1.78B |
| Total Liabilities | 41.4M | 165M | 10.9M | 20.4M | 21.2M | 27.6M | 30.3M | 147M |
| Shareholders' Equity | -16.9M | -33.4M | 274M | 347M | 319M | 459M | 522M | 1.63B |
| Cash & Short-term Investments | 23.7M | 129M | 281M | 352M | 318M | 470M | 530M | 1.74B |
| Total Debt | 40.3M | 160M | - | 4.41M | 5.41M | 4.74M | 3.99M | 3.38M |
| Cash Flow | ||||||||
| Operating Cash Flow | -9.17M | -14.6M | -33.5M | -52.6M | -91.9M | -109M | -144M | -218M |
| Capital Expenditure | 180K | 203K | 668K | 5.55M | 5.75M | 1.31M | 256K | 412K |
| Free Cash Flow | -9.35M | -14.8M | -34.2M | -58.2M | -97.7M | -110M | -144M | -218M |
| Ratios | ||||||||
| ROE | - | - | -15.4% | -4.4% | -31.4% | -29.1% | -32.1% | 86.6% |
| ROA | -38.7% | -13.0% | -14.8% | -4.2% | -29.5% | -27.5% | -30.4% | 79.4% |
| Debt to Equity | - | - | - | 0.01x | 0.02x | 0.01x | 0.01x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Edgewise Therapeutics Inc dividends
Edgewise Therapeutics Inc has not paid dividends in the last 7 fiscal years.
Who owns Edgewise Therapeutics Inc
- Insiders 0.62%
- Institutions 99.38%
- Public & others 0.00%
- Shares outstanding 109M
- Free float 75.1M
Top funds holding EWTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.92M | 2.67% | +0.30% | Sep 2026 |
| iShares Russell 2000 ETF | 1.82M | 1.66% | 0.00% | Oct 2026 |
| American Century Small Cap Growth Inv | 856K | 0.78% | 0.00% | Sep 2026 |
| Victory Pioneer Select Mid Cap Growth A | 794K | 0.73% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 783K | 0.72% | +0.15% | Aug 2026 |
| Janus Henderson Global Life Sciences D | 764K | 0.70% | 0.00% | Sep 2026 |
| Janus Henderson Triton D | 760K | 0.69% | 0.00% | Sep 2026 |
| Janus Henderson Hrzn Biotec E2 USD | 749K | 0.68% | 0.00% | Jun 2026 |
| Janus Global Life Science AUSD | 746K | 0.68% | +15.06% | Sep 2026 |
| Janus Henderson Glb Life Scn I2 USD | 732K | 0.67% | +2.44% | Aug 2026 |
| Fidelity Select Biotechnology | 699K | 0.64% | 0.00% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 671K | 0.61% | -0.38% | Oct 2026 |
| iShares Biotechnology ETF | 637K | 0.58% | -0.19% | Oct 2026 |
| Driehaus Small Cap Growth Institutional | 600K | 0.55% | +5.84% | Sep 2026 |
| Janus Henderson Venture D | 486K | 0.44% | 0.00% | Sep 2026 |
| Heptagon Driehaus US Micro Cap Eq C$ Acc | 467K | 0.43% | 0.00% | Sep 2026 |
| AB Small Cap Growth A | 446K | 0.41% | -2.51% | Sep 2026 |
| Heptagon Driehaus US Sm Cp Eq C USD Acc | 435K | 0.40% | -7.62% | Sep 2026 |
| Candriam Eqs L Biotech C USD Cap | 435K | 0.40% | -2.88% | Apr 2026 |
| Schwab US Small-Cap ETF™ | 433K | 0.40% | +0.24% | Oct 2026 |
Top institutions holding EWTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Orbimed Advisors LLC | 15.5M | 14.17% | 0.00% | Jun 2026 |
| Paradigm Biocapital Advisors LP | 10.2M | 9.33% | +38.70% | Jun 2026 |
| RA Capital Management, LLC | 8.39M | 7.67% | -19.52% | Jun 2026 |
| BlackRock Inc | 6.61M | 6.03% | +2.06% | Jun 2026 |
| Jupiter Topco LLC | 6.08M | 5.55% | 0.00% | Jun 2026 |
| FMR Inc | 5.49M | 5.01% | +439.71% | Jun 2026 |
| Novo A/S | 5.35M | 4.89% | 0.00% | Jun 2026 |
| Driehaus Capital Management LLC | 4.73M | 4.32% | +5.60% | Jun 2026 |
| Perceptive Advisors LLC | 4.37M | 4.00% | -1.13% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.86M | 3.53% | +1.91% | Jun 2026 |
| Baker Bros Advisors LP | 3.70M | 3.38% | -43.71% | Jun 2026 |
| Siren, L.L.C. | 3.18M | 2.91% | -28.12% | Jun 2026 |
| Cormorant Asset Management, LLC | 2.51M | 2.29% | -23.01% | Jun 2026 |
| Geode Capital Management, LLC | 2.17M | 1.99% | +21.47% | Jun 2026 |
| AllianceBernstein L.P. | 2.12M | 1.94% | +23.04% | Jun 2026 |
| Integral Health Asset Management, LLC | 2.00M | 1.83% | +25.00% | Jun 2026 |
| BRAIDWELL LP | 2.00M | 1.82% | -14.94% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.95M | 1.78% | -13.24% | Jun 2026 |
| State Street Corp | 1.83M | 1.67% | +6.47% | Jun 2026 |
| MPM Oncology Impact Management LP | 1.62M | 1.48% | -2.40% | Jun 2026 |
Edgewise Therapeutics Inc company profile
- Company name
- Edgewise Therapeutics Inc
- Ticker
- EWTX.US
- Exchange
- USA Stocks
- Listed since
- Mar 26, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 133
- Fiscal year end
- December
- Address
- 1715 38th Street, Boulder, CO, United States, 80301
- Phone
- 720 262 7002
- Website
- edgewisetx.com
About Edgewise Therapeutics Inc
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Edgewise Therapeutics Inc management
9- Dr. Peter A. Thompson FACP, M.D.Co-Founder & Independent Chairman · born 1960
- Dr. Kevin Koch Ph.D.President, CEO & Director · born 1960
- Dr. Badreddin Edris Ph.D.Co-Founder & Independent Director · born 1987
- Dr. Alan J. Russell Ph.D.Co-Founder, Chief Scientific Officer & Director · born 1970
- Mr. Michael P. NofiChief Financial Officer · born 1971
- Dr. Behrad Derakhshan Ph.D.Chief Operating Officer · born 1980
- Dr. Joanne M. Donovan M.D., Ph.D.Chief Medical Officer · born 1957
- Mr. John R. Moore J.D.General Counsel · born 1964
- Dr. Aylin TugcuSenior Vice President of Cardiovascular Clinical Development & Medical Affairs